Among them, imatinib was the first targeted antitumor drug [27], which was first approved in 2001 for the treatment of BCR-ABL–positive and Philadelphia chromosome–positive CML [3,6]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.